Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome

Luigi Ferini-Strambi, Sara Marelli, Andrea Galbiati

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Restless legs syndrome/Willis Ekbom disease (RLS/WED) is a sensorimotor disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them, that typically occurs and tend to worsen in the evening/night or during period of inactivity. Standard medications for RLS/WED are dopamine agonists and calcium channel α-2-δ ligands. The clinical spectrum of RLS/WED is very broad, ranging from individuals suffering from the disease during limited periods up to those severely affected, with daily symptoms. In such cases a long-acting drug like rotigotine should be considered. Areas covered: The clinical pharmacology and efficacy of rotigotine was examined to evaluate the evidence supporting its use in RLS/WED. Expert opinion: The rotigotine transdermal patch provides constant delivery of the drug, maintaining a stable plasma concentration over 24 hours by means of a single daily application. Several randomized, double-blind, placebo-controlled trials have demonstrated the efficacy of rotigotine in improving moderate-to-severe RLS/WED symptoms. Rotigotine is generally well tolerated. The most common adverse effects were application-site reactions, dose-dependent, more frequently reported in the first period of treatment. Incidence of augmentation in RLS/WED patients treated with oral dopamine agonists is higher when compared with the use of transdermal rotigotine.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalExpert Opinion on Drug Metabolism and Toxicology
DOIs
Publication statusAccepted/In press - Jun 17 2016

Fingerprint

Restless Legs Syndrome
Clinical Pharmacology
Dopamine Agonists
Therapeutics
Calcium Channels
N 0437
Pharmaceutical Preparations
Transdermal Patch
Ligands
Plasmas
Expert Testimony
Leg

Keywords

  • adverse events
  • augmentation
  • dopamine agonists
  • restless leg syndrome
  • Rotigotine

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{f6406a4721ba44a681ce2c52f053895c,
title = "Clinical pharmacology and efficacy of rotigotine (Neupro{\circledR} patch) in the treatment of restless leg syndrome",
abstract = "Introduction: Restless legs syndrome/Willis Ekbom disease (RLS/WED) is a sensorimotor disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them, that typically occurs and tend to worsen in the evening/night or during period of inactivity. Standard medications for RLS/WED are dopamine agonists and calcium channel α-2-δ ligands. The clinical spectrum of RLS/WED is very broad, ranging from individuals suffering from the disease during limited periods up to those severely affected, with daily symptoms. In such cases a long-acting drug like rotigotine should be considered. Areas covered: The clinical pharmacology and efficacy of rotigotine was examined to evaluate the evidence supporting its use in RLS/WED. Expert opinion: The rotigotine transdermal patch provides constant delivery of the drug, maintaining a stable plasma concentration over 24 hours by means of a single daily application. Several randomized, double-blind, placebo-controlled trials have demonstrated the efficacy of rotigotine in improving moderate-to-severe RLS/WED symptoms. Rotigotine is generally well tolerated. The most common adverse effects were application-site reactions, dose-dependent, more frequently reported in the first period of treatment. Incidence of augmentation in RLS/WED patients treated with oral dopamine agonists is higher when compared with the use of transdermal rotigotine.",
keywords = "adverse events, augmentation, dopamine agonists, restless leg syndrome, Rotigotine",
author = "Luigi Ferini-Strambi and Sara Marelli and Andrea Galbiati",
year = "2016",
month = "6",
day = "17",
doi = "10.1080/17425255.2016.1194393",
language = "English",
pages = "1--9",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome

AU - Ferini-Strambi, Luigi

AU - Marelli, Sara

AU - Galbiati, Andrea

PY - 2016/6/17

Y1 - 2016/6/17

N2 - Introduction: Restless legs syndrome/Willis Ekbom disease (RLS/WED) is a sensorimotor disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them, that typically occurs and tend to worsen in the evening/night or during period of inactivity. Standard medications for RLS/WED are dopamine agonists and calcium channel α-2-δ ligands. The clinical spectrum of RLS/WED is very broad, ranging from individuals suffering from the disease during limited periods up to those severely affected, with daily symptoms. In such cases a long-acting drug like rotigotine should be considered. Areas covered: The clinical pharmacology and efficacy of rotigotine was examined to evaluate the evidence supporting its use in RLS/WED. Expert opinion: The rotigotine transdermal patch provides constant delivery of the drug, maintaining a stable plasma concentration over 24 hours by means of a single daily application. Several randomized, double-blind, placebo-controlled trials have demonstrated the efficacy of rotigotine in improving moderate-to-severe RLS/WED symptoms. Rotigotine is generally well tolerated. The most common adverse effects were application-site reactions, dose-dependent, more frequently reported in the first period of treatment. Incidence of augmentation in RLS/WED patients treated with oral dopamine agonists is higher when compared with the use of transdermal rotigotine.

AB - Introduction: Restless legs syndrome/Willis Ekbom disease (RLS/WED) is a sensorimotor disorder characterized by unpleasant sensations in the legs accompanied by an urge to move them, that typically occurs and tend to worsen in the evening/night or during period of inactivity. Standard medications for RLS/WED are dopamine agonists and calcium channel α-2-δ ligands. The clinical spectrum of RLS/WED is very broad, ranging from individuals suffering from the disease during limited periods up to those severely affected, with daily symptoms. In such cases a long-acting drug like rotigotine should be considered. Areas covered: The clinical pharmacology and efficacy of rotigotine was examined to evaluate the evidence supporting its use in RLS/WED. Expert opinion: The rotigotine transdermal patch provides constant delivery of the drug, maintaining a stable plasma concentration over 24 hours by means of a single daily application. Several randomized, double-blind, placebo-controlled trials have demonstrated the efficacy of rotigotine in improving moderate-to-severe RLS/WED symptoms. Rotigotine is generally well tolerated. The most common adverse effects were application-site reactions, dose-dependent, more frequently reported in the first period of treatment. Incidence of augmentation in RLS/WED patients treated with oral dopamine agonists is higher when compared with the use of transdermal rotigotine.

KW - adverse events

KW - augmentation

KW - dopamine agonists

KW - restless leg syndrome

KW - Rotigotine

UR - http://www.scopus.com/inward/record.url?scp=84976900080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976900080&partnerID=8YFLogxK

U2 - 10.1080/17425255.2016.1194393

DO - 10.1080/17425255.2016.1194393

M3 - Article

AN - SCOPUS:84976900080

SP - 1

EP - 9

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

ER -